evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Sublingual immunotherapy vs control

Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma

It is very uncertain whether sublingual immunotherapy changes exacerbation requiring ED or hospital visit Weighted mean duration… compared with control (very low certainty).

1 finding from 1 review

Sublingual immunotherapy vs control

Serious adverse events Weighted mean duration of studies: 49 weeks · people with asthma

Sublingual immunotherapy showed no clear difference in serious adverse events Weighted mean duration of studies: 56 weeks compared with control (moderate certainty).

1 finding from 1 review

Sublingual immunotherapy vs control

Exacerbation requiring OCS Weighted mean duration of studies: 25 weeks · people with asthma

It is very uncertain whether sublingual immunotherapy changes exacerbation requiring OCS Weighted mean duration of studies: 58 weeks compared with control (very low certainty).

1 finding from 1 review

Sublingual immunotherapy vs control

All adverse events Weighted mean duration of studies: 60 weeks** · people with asthma

Sublingual immunotherapy leads to higher all adverse events Weighted mean duration of studies: 62 weeks** compared with control (high certainty).

1 finding from 1 review

Sclerotherapy vs placebo

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).

1 finding from 1 review

Sclerotherapy vs placebo

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy probably leads to higher adverse events ‐ matting ( compared with placebo (moderate certainty).

1 finding from 1 review